We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Illumina, Inc. (ILMN - Free Report) has announced preliminary revenue results for first-quarter 2020 on Apr 14. The company is slated to release its full financial results for the period on Apr 30.
Per Illumina, the overall preliminary results for the first quarter of 2020 were robust but the second quarter is expected to be significantly affected by the coronavirus pandemic and the related disruptions. Following the announcement, its shares gained 2.9% to close at $297.88 yesterday.
In the to-be-reported quarter, Illumina expects a rise in total revenues of 1.4% on a year-over-year basis to $858 million, subject to quarter-end closing adjustments. The top line is expected to primarily benefit from strong sequencing consumable revenues. However, this is expected to be partly dented by the impact of the coronavirus outbreak, which included disrupted system sales toward the quarter-end. The Zacks Consensus Estimate for the metric is currently pegged at $832.2 million.
However, the company withdrew its 2020 revenue and earnings per share guidance as it is not in a position to estimate the extent of severity and duration of the outbreak. However, per Illumina, the current situation is a temporary one, which will not affect long-term sequencing adoption and demand.
Currently, Illumina is redirecting its focus on ensuring supply continuity for its customers, which include those performing critical clinical testing for patients. It is also supporting researchers, who are using sequencing to track transmission, study the evolution of the virus’ genome, and assess the impact of the effectiveness of diagnostics and therapies. Researchers are also using Illumina’s sequencing products to explore the possibilities of adopting surveillance to reduce the impact of future outbreaks of new infectious diseases.
Share Price Movement
The company has underperformed its industry over the past three months. The stock has slipped 8.6% compared with a 4.3% decline of the industry.
Zacks Rank & Key Picks
Illumina currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are ResMed Inc. (RMD - Free Report) , National Vision Holdings, Inc. (EYE - Free Report) and Phibro Animal Health Corporation (PAHC - Free Report) .
National Vision’s long-term earnings growth rate is estimated at 10.7%. The company presently has a Zacks Rank #2.
Phibro’s long-term earnings growth rate is estimated at 2.1%. It currently carries a Zacks Rank #2.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.
This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.
Image: Bigstock
Illumina (ILMN) Posts Q1 Preliminary Results, Withdraws View
Illumina, Inc. (ILMN - Free Report) has announced preliminary revenue results for first-quarter 2020 on Apr 14. The company is slated to release its full financial results for the period on Apr 30.
Per Illumina, the overall preliminary results for the first quarter of 2020 were robust but the second quarter is expected to be significantly affected by the coronavirus pandemic and the related disruptions. Following the announcement, its shares gained 2.9% to close at $297.88 yesterday.
In the to-be-reported quarter, Illumina expects a rise in total revenues of 1.4% on a year-over-year basis to $858 million, subject to quarter-end closing adjustments. The top line is expected to primarily benefit from strong sequencing consumable revenues. However, this is expected to be partly dented by the impact of the coronavirus outbreak, which included disrupted system sales toward the quarter-end. The Zacks Consensus Estimate for the metric is currently pegged at $832.2 million.
However, the company withdrew its 2020 revenue and earnings per share guidance as it is not in a position to estimate the extent of severity and duration of the outbreak. However, per Illumina, the current situation is a temporary one, which will not affect long-term sequencing adoption and demand.
Currently, Illumina is redirecting its focus on ensuring supply continuity for its customers, which include those performing critical clinical testing for patients. It is also supporting researchers, who are using sequencing to track transmission, study the evolution of the virus’ genome, and assess the impact of the effectiveness of diagnostics and therapies. Researchers are also using Illumina’s sequencing products to explore the possibilities of adopting surveillance to reduce the impact of future outbreaks of new infectious diseases.
Share Price Movement
The company has underperformed its industry over the past three months. The stock has slipped 8.6% compared with a 4.3% decline of the industry.
Zacks Rank & Key Picks
Illumina currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are ResMed Inc. (RMD - Free Report) , National Vision Holdings, Inc. (EYE - Free Report) and Phibro Animal Health Corporation (PAHC - Free Report) .
ResMed has a projected long-term earnings growth rate of 14.4%. It currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
National Vision’s long-term earnings growth rate is estimated at 10.7%. The company presently has a Zacks Rank #2.
Phibro’s long-term earnings growth rate is estimated at 2.1%. It currently carries a Zacks Rank #2.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.
This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.
See their latest picks free >>